share_log

港股异动 | 名创优品(09896)涨超7% IP联名爆款频出 机构指其二季度业绩有望超预期

Changes in Hong Kong stocks | Mingchuang Premium (09896) rose more than 7%, and frequent IP co-sales, institutions say its second-quarter results are expected to exceed expectations

Zhitong Finance ·  Apr 17 23:14

The Zhitong Finance App learned that Mingchuang Premium (09896) rose by more than 7%. As of press release, it had risen 7.08% to HK$41.6, with a turnover of HK$656.935 million.

According to the news, Mingchuang Premium previously launched a blockbuster IP, the Chiikawa co-branded product in the country at Joy City in Shanghai. According to reports, the sales volume of the first store reached 2.68 million yuan in 10 hours, the three-day sales performance of the first store was 8 million yuan, and the customer unit price was over 1,000 yuan. Zheshang Securities pointed out that Mingchuang Premium has established cooperative relationships with more than 80 IPs around the world, leading its peers in IP asset reserves. Furthermore, the IP co-branding strategy has been tried and tested, and past sales performance has exceeded expectations. The bank believes that this major IP launch will significantly drive sales growth, and second-quarter results are expected to exceed expectations.

Tianfeng Securities previously pointed out that in January-February '24, the GMV of Mingchuang Premium China's offline stores increased by about 13%. Compared with the recovery in same-store sales of 95% in the same period last year, the overseas GMV also increased by about 40%. In the future, the company will continue to participate in global competition from the two dimensions of cost leadership and product differentiation, always adhering to the basic cost performance market, while actively experimenting with the supermarket strategy, locking in “big beauty,” “big toys,” and “big IP,” building a strong brand image and super category, and further enhancing the GMV of a single store.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment